Bladder cancer is the most common malignancy of the urinary tract, having one of the highest recurrence rates and progression from non-muscle to muscle invasive bladder cancer that commonly leads to metastasis.
The human microbiome has been linked to the development of several malignancies, but there is scarcity of data on the microbiome of bladder cancer patients. In this study, we analyzed microbial composition and diversity among patients with and without bladder cancer.
Renal cell carcinoma (RCC) rates are increasing worldwide, with high mortality and a high proportion of patients asymptomatic at diagnosis – so should we be screening for RCC?
Though simple in its definition – a protrusion out of the bladder wall – the pathogenesis of bladder diverticulum (BD) may be quite diverse ranging from congenital to chronic or benign to malignant. The management of BD may also be technically nuanced with a myriad of approaches dictated by clinical scenarios. As surgeons, we must […]
San Francisco, CA (UroToday.com) — The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial, which will enroll […]
Bladder cancer is a major urological disease, with approximately 550 000 new cases diagnosed in 2018. We examined gender-specific incidence and mortality patterns, and trends of bladder cancer from a global perspective.
Limited information is available regarding complications associated with kidney-sparing ureteroscopic management of low-grade upper tract urothelial carcinoma (UTUC). To identify the associated complications rates and contributing factors, we examined data from relevant clinical studies.
Accumulating evidence supports the significance of aberrant alternative splicing (AS) events in cancer; however, genome-wide profiling of progression-free survival (PFS)-related AS events in testicular germ cell tumors (TGCT) has not been reported.
Targeting VEGFR-2 signaling pathway is well-established as an important approach for the treatment of solid tumors, particularly renal cancer. Herein, novel indolyl-1,2,4-triazole hybrids were designed and synthesized as VEGFR-2 kinase inhibitors with potential anti-renal cancer activity.
Prostate-specific membrane antigen (PSMA; also termed glutamate carboxypeptidase II (GCP II)) is abundantly expressed in prostate cancer. It has been shown recently that PSMA is expressed in neovasculature of differentiated thyroid cancer.
